Lexicon Pharmaceuticals (LXRX) Posts Q3 Loss of 6c/Share
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.23 -0.45%
Revenue Growth %: -78.9%
Financial Fact:
Total operating expenses: 62.65M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -78.9%
Financial Fact:
Total operating expenses: 62.65M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q3 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $372 thousand versus the consensus estimate of $600 thousand.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- HSBC lifts S&P 500 year-end target
- Bernstein SocGen Group Reiterates Outperform Rating on Robinhood Markets (HOOD)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
